http://merutt.wordpress.com/2010/02...nstitute-forsker-pa-medisiner-for-xmrv-og-me/ National Cancer Institute forsker p medisiner for XMRV og ME Arkivert under: Uncategorized Rutt @ 16:33 Tags: cfs, me, merutt, myalgisk encefalopati, National Cancer Institute, rutt, thisisme, WPI, XMRV National Cancer Institute med Sandra K. Ruscetti Ph.D, Head, Retroviral Pathogenesis Section, skriver flgende p sine web-sider: Cancer and Neuroimmune Diseases Induced by the Human Retrovirus XMRV We are currently using knowledge and reagents obtained from working with mouse retroviruses to study the xenotropic MuLV-related human retrovirus XMRV, which was recently discovered through an association with prostate cancer. In collaboration with the laboratories of Judy Mikovits and Frank Ruscetti, we were able to use antibodies developed against the envelope protein of SFFV to detect infectious XMRV in the blood cells and plasma of patients suffering from the neuroimmune disease chronic fatigue syndrome (CFS). We were further able to develop a seroconversion assay using cells expressing the SFFV envelope protein to detect antibodies against the virus in the plasma of CFS patients. We now plan to apply our knowledge of the pathogenesis of mouse retroviruses that cause cancer and neurological disease in rodents to study the molecular basis for similar diseases associated with XMRV. We are in the process of developing rodent models for determining the biological effects of XMRV in vivo, which if successful will provide a small animal model for preclinical testing of potential anti-XMRV drugs. In addition, we are testing both in vitro and in vivo the biological effects of the envelope protein of XMRV, which like its related SFFV counterpart may be responsible for the pathogenicity of XMRV. Collaborators: Collaborators on this research are Dr. Frank Ruscetti, Laboratory of Experimental Immunology, CCR, NCI; Dr. Larry Keefer, Laboratory of Comparative Carcinogenesis, CCR, NCI; Dr. Judy Mikovits, Whittemore Peterson Institute; Drs. Candace Pert and Michael Ruff, RAPID Pharmaceuticals.